| Number: 201303012 |
Principal Investigator: Schroeder, Mark |
| Title: Phase I/II Trial of Intravenous Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation |
| Description: This research study aims to discover the side effects and highest dose of a drug called
azacitidine that can be given after a stem cell transplant to help prevent or minimize the effects of graft-versus-host disease (GVHD). We will also look at the way azacitidine might affect whether or how a pers...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201210102 |
Principal Investigator: Welch, John |
| Title: Genomic Predictors of Decitabine Response in AML/MDS |
| Description: The purpose of this research study is to identify genetic markers which will help us predict who will respond to treatment with a drug called decitabine and who will not. Typically, between 20 and 30% of patients with AML and MDS will achieve a complete response with decitabine, while the remaining...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201108380 |
Principal Investigator: Westervelt, Peter |
| Title: A Phase I Study of the Safety and Feasibility of Azacitidine after Donor Lymphocyte Infusion for Patients with Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome after Allogeneic Stem Cell Transplantation |
| Description: The purpose of this research study is to determine whether it is safe to give patients azacitidine after administering donor lymphocytes, and whether doing this will reduce patients’ chances of experiencing Graft vs. Host Disease (GvHD)....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201108378 |
Principal Investigator: Pusic, Iskra |
| Title: Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome |
| Description: The goal of this study is to determine the best dose of decitabine given after a transplant as maintenance therapy.
We will also evaluate how effective decitabine is in getting rid of remaining disease and providing disease control, by allowing the graft (donor T-cells) to attack and control the ...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201107117 |
Principal Investigator: Vij, Ravi |
| Title: A Phase I Trial of Carfilzomib in Adult Patients with Relapsed Acute Myeloid and Acute Lymphoblastic Leukemia |
| Description: You may be asked to participate in this study if you have Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) and your AML or ALL has come back after chemotherapy. The goal of this study is to determine the best dose of carfilzomib for treatment of these cancers....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201106039 |
Principal Investigator: Uy, Geoffrey |
| Title: Chemosensitization with Plerixafor Plus G-CSF in Relapsed or Refractory Acute Myeloid Leukemia |
| Description: The purpose of the first phase of the study is to learn what dose of an investigational drug, plerixafor along with G-CSF can be safely given with standard of care chemotherapy drugs.
Once the first phase of the study is completed, the second phase of the study will determine whether the combin...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201104323 |
Principal Investigator: Uy, Geoffrey |
| Title: A Pilot Study of G-CSF to Disrupt the Bone Marrow Microenvironment in Relapsed or Refractory Acute Lymphoblastic Leukemia |
| Description: The purpose of this research study is to see whether G-CSF given in combination with ifosfamide, etoposide, and dexamethasone is safe in treating ALL....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201101810 |
Principal Investigator: Schroeder, Mark |
| Title: A Phase I Trial Evaluating the Effects of Plerixafor (AMD3100) and G-CSF in Combination with Azacitidine (Vidaza) for the Treatment of MDS |
| Description: The overall purpose of this research is to evaluate the safety and tolerability of the combination of plerixafor, G-CSF, and azacitidine for the treatment of MDS....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201101749 |
Principal Investigator: Vij, Ravi |
| Title: Phase I/II Trial of Azacitidine plus Lenalidomide in the Treatment of Acute Myeloid Leukemia |
| Description: The purpose of this study is to test the safety of the combination of various dose levels of lenalidomide and azacitidine in patients with AML. This research is being done because the current chemotherapy options for AML in patient 60 years and above and in patients in whom the AML has not responde...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201011810 |
Principal Investigator: Vij, Ravi |
| Title: Phase II Trial of High Dose Lenalidomide in Patients with Myelodysplastic Syndrome Refractory to Hypomethylating Agents
|
| Description: The purpose of this research study is to see how patients with MDS that is not responsive to standard treatment respond to high dose lenalidomide followed by low dose lenalidomide....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201111096 |
Principal Investigator: Westervelt, Peter |
| Title: Multi-center single arm Phase II Study of Myeloablative Allogeneic Stem Cell Transplantation for non-remission Acute Myeloblastic Leukemia (AML) using Clofarabine and Busulfan x 4 (CloBu4) regimen |
| Description: The purpose of this research study is to study a new method of full intensity, pre-treatment (or conditioning) called CloBu4, using the drugs Clofarabine and Busulfan....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201102463 |
Principal Investigator: Fehniger, Todd |
| Title: KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor |
| Description: This study is investigating a newer donor selection factor, KIR genotyping, in addition to HLA testing and other donor selection factors....MORE |
| ___________________________________________________________________________________________________ |
| Number: CTSU S0805 |
Principal Investigator: Uy, Geoffrey |
| Title: Phase II Study of Combination of Hyper-CVAD and Dasatinib with or without allogeneic stem cell transplant in Patients with Philadelphia (Ph)
Chromosome Positive and/or Bcr-Abl Positive Acute LymphoblasticLeukemia (ALL) (A BMT Study) |
| Description: This trial is studying the side effects of giving combination chemotherapy together with or without donor stem cell transplant and to see how well it works in treating patients with acute lymphoblastic leukemia....MORE |
| ___________________________________________________________________________________________________ |
| Number: CTSU E2906 |
Principal Investigator: Uy, Geoffrey |
| Title: Phase III Randomized Trial of Clofarabine as Induction and Post- Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >= 60 Years) |
| Description: This trial is studying clofarabine to see how well it works compared with daunorubicin hydrochloride and cytarabine when followed by decitabine or observation in treating older patients with newly diagnosed acute myeloid leukemia....MORE |
| ___________________________________________________________________________________________________ |
| Number: CTSU CIRB S1203 |
Principal Investigator: Uy, Geoffrey |
| Title: A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
|
| Description: The purpose of this study is to compare the effects, good and/or bad of three drug combinations. We want to see if the study treatments will get rid of leukemia cells and keep them from coming back to prepare a patient who may benefit from stem cell transplant....MORE |
| ___________________________________________________________________________________________________ |
| Number: CALGB 10801 |
Principal Investigator: Uy, Geoffrey |
| Title: A Phase II Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy Plus Dasatinib (NSC #732517, IND #73969) and Continuation Therapy with Dasatinib Alone in Newly Diagnosed Patients with Core Binding Factor Acute Myeloid Leukemia (AML) |
| Description: The purpose of this study is to test the safety and effectiveness of the addition of the drug dasatinib to a treatment regimen for patients with AML, and to see what effects (good and bad) dasatinib has on patients and their leukemia....MORE |
| ___________________________________________________________________________________________________ |
| Number: CALGB 10701 |
Principal Investigator: Uy, Geoffrey |
| Title: A Phase II Study of Dasatanib (Sprycel®) (IND #73969, NSC #732517) as Primary Therapy Followed by Transplantation for Adults = 50 Years with Newly Diagnosed PH+ Acute Lymphoblastic Leukemia by CALGB, ECOG, SWOG, AND NCIC CTG |
| Description: The purpose of this study is find out what effects (good and bad) an experimental drug known as dasatinib has on patients and their leukemia....MORE |
| ___________________________________________________________________________________________________ |
| Number: CALGB 100701 |
Principal Investigator: Vij, Ravi |
| Title: Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL) |
| Description: The purpose of this study is to find out what effects (good and bad) this treatment has on patients and this type of cancer.
This research is being done to improve the outcomes of patients diagnosed with chronic lymphocytic leukemia who may have high risk features or who have had their disease r...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201212100 |
Principal Investigator: Bartlett, Nancy |
| Title: An Open-label, Single arm, Multicenter Phase 2 Study of the Bruton’s Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma with 17p Deletion |
| Description: The purpose of this study is to test whether or not the investigational study drug, PCI-32765(ibrutinib) works and is safe in patients with CLL / SLL with 17p deletion....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201212075 |
Principal Investigator: Wagner-Johnston, Nina |
| Title: A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of GS 1101 (CAL-101) in Combination with Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia |
| Description: The purpose of this study is to provide more information about whether giving ofatumumab and GS 1101 together is effective and safe for treating people with CLL....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201210068 |
Principal Investigator: Uy, Geoffrey |
| Title: Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine: Daunorubicin) Liposome Injection versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age with Untreated High Risk (Secondary) AML |
| Description: This study is designed to help us learn more about the investigational study drug, CPX-351, in elderly patients who are newly diagnosed with high risk (secondary) leukemia and have not received any treatment for the disease. Through this study, we plan to learn how safe CPX-351 is and how effective...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201207089 |
Principal Investigator: Bartlett, Nancy |
| Title: Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination with Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
| Description: The purpose of this study is to examine the safety and efficacy of Ibrutinib administered in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201206065 |
Principal Investigator: Uy, Geoffrey |
| Title: A Phase I, open, dose escalation trial with BI 836858 in patients with refractory or relapsed acute myeloid leukemia |
| Description: The purpose of this research study is to identify the highest dose of the study drug BI 836858 that does not cause unacceptable side effects and to obtain information on the safety and effectiveness of BI 836858....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201205111 |
Principal Investigator: Fehniger, Todd |
| Title: A Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients with High Risk Acute Myeloid Leukemia in First Complete Remission (CR1) |
| Description: This study is being done to evaluate a drug called CNDO-109 Activated Allogeneic Natural Killer Cells and how patients with Acute Myeloid Leukemia (AML) respond when given this therapy....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201205103 |
Principal Investigator: DiPersio, John |
| Title: Study of the Anti-EphA3 Monoclonal Antibody KB004 in Subjects with EphA3-Expressing Hematologic Malignancies |
| Description: The main purpose of this clinical research study is to find the highest tolerable dose of the study drug KB004, which is being tested as a possible therapy for people with different
types of blood cancer (leukemia
as well as other blood cancers). This study will also explore whether KB004 is safe fo...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201204052 |
Principal Investigator: DiPersio, John |
| Title: A randomized, prospective, double blind, placebo-controlled, phase 3 study of US-ATG-F prophylaxis as a supplement to standard of care prophylaxis to prevent moderate to severe chronic GVHD in adult acute myeloid leukemia, acute lymphoid leukemia, and myelodysplastic syndrome patients after allogeneic stem cell transplantation from unrelated donors
|
| Description: The purpose of this study is to find out if an investigational drug called US-ATG-F can be safely used to prevent graft versus host disease (GVHD)....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201202062 |
Principal Investigator: DiPersio, John |
| Title: A phase 1b study to evaluate the safety and preliminary Efficacy of pf-04449913, an oral hedgehog inhibitor, in Combination with intensive chemotherapy, low dose ara-c or Decitabine in patients with acute myeloid leukemia or high risk
Myelodysplastic syndrome
|
| Description: The purpose of this research study is to learn about the effects of the study drug, PF-04449913, in combination with chemotherapy, and to find the best dose of PF-04449913 for treating AML and high risk MDS....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201202024 |
Principal Investigator: Abboud, Camille |
| Title: A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms |
| Description: The purpose of this research study is to see how safe an LY2784544 (an investigational drug) is and test how well it will work to help people with myeloproliferative neoplasms....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201112110 |
Principal Investigator: Westervelt, Peter |
| Title: A Phase 3, Multicenter, Randomized Study to Evaluate the Substitution of Marqibo® (Vincristine Sulfate Liposomes Injection, VSLI) for Standard Vincristine Sulfate Injection (VSI) in the Induction, Intensification, and Maintenance Phases of Combination Chemotherapy in the Treatment of Subjects >/= 60 Years Old with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) |
| Description: The purposes of this research study are:
To compare the overall survival in patients 60-years of age and older who are newly diagnosed with ALL and treated with a combination chemotherapy which includes either VSI or Marqibo
To compare the side effects between the 2 chemotherapy treatment grou...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201111095 |
Principal Investigator: DiPersio, John |
| Title: An Open Label, Multicenter, Phase II Study to Evaluate Efficacy and Safety of the BiTE antibody blinatumomab in Adult Patients with Relapsed/Refractory B-precursor acute lymphoblastic leukemia (ALL) |
| Description: The purpose of this research study is to find out how safe a continuous infusion of blinatumomab is and how well it works in patients with B-precursor ALL who have not responded to previous therapy or have suffered a relapse....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201109095 |
Principal Investigator: Uy, Geoffrey |
| Title: A Phase 2, Multicenter, Randomized, Open Label, Parallel-Group Study of a Lenalidomide (Revlimid®) Regimen or a Sequential Azacitidine (Vidaza®) plus Lenalidomide (Revlimid®) Regimen versus Conventional Care Regimens for Therapy of Older Subjects with Newly Diagnosed Acute Myeloid Leukemia |
| Description: The purpose of this study is to see if the drug lenalidomide alone or in combination with the drug azacitidine is safe and effective for use in people 65 years and older with AML. This study is being conducted to determine if these drugs will help patients with AML more than currently available tr...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201103345 |
Principal Investigator: Wagner-Johnston, Nina |
| Title: A Phase I Study to Investigate the Safety and Clinical Activity of CAL-101 in Combination with Chemotherapeutic Agents and Anti-CD20 mAb in Patients with Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia |
| Description: The purpose of this study is to see if an investigational drug named CAL-101 in combination with rituximab and bendamustine is safe to give to people with certain types of cancer and to see how it affects patients and their cancer....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201301154 |
Principal Investigator: Dehdashti, Farrokh |
| Title: Imaging of Patients after Infusion of Haploidentical Genetically Modified T cells: A Pilot Study of Tracking and Toxicity and a companion to the protocol: “TK008: Randomized phase III trial of haploidentical HCT with or without an add back strategy of HSV-Tk donor lymphocytes in patients with high risk acute leukemia |
| ___________________________________________________________________________________________________ |
| Number: 201011766 |
Principal Investigator: Westervelt, Peter |
| Title: Tissue Acquisition for Analysis of Genetic Progression Factors in Hematologic Diseases |
| ___________________________________________________________________________________________________ |
| Number: 201105062 |
Principal Investigator: Druley, Todd |
| Title: Whole Exome Sequencing of Matched Pairs for Infants with Acute Lymphoblastic Leukemia |
| ___________________________________________________________________________________________________ |
| Number: 201102097 |
Principal Investigator: DiPersio, John |
| Title: Part I of an Assessment of Allogeneic Hematopoietic Stem Cell Transplantation in Medicare Beneficiaries with Myelodysplastic Syndrome and Related Disorders |
| ___________________________________________________________________________________________________ |